CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 98 enrolled
Drug / intervention
A-101 Solution 40 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02669862
NCT02669862Phase 2Completed

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Solution in Subjects With Common Warts.

Aclaris Therapeutics, Inc.·interventional·Posted Feb 1, 2016·Updated Dec 7, 2018

In Brief

A Phase 2 clinical trial evaluating A-101 Solution 40, A-101 Solution 45, and 1 other intervention for Common Warts. Completed, enrolled 98 participants across 1 site.

Detailed Summary

This is a randomized, double-blind, vehicle-controlled, parallel-group study with 3 treatment groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Warts
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 1, 2016
Enrollment StartDec 21, 2015
Primary CompletionSep 16, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.4 years ago

Interventions

A-101 Solution 40drug

A-101 Solution 45drug

Vehicle Solutiondrug